A method for determining the predisposition of a patient to altered biotransformation and the development of adverse drug reactions in a treatment of the patient with atorvastatin

摘要

The present invention relates to a method for determining a predisposition of a patient for the development of muscle diseases and / or to altered biotransformation in a treatment of the patient with atorvastatin. In this case, the presence of at least one single nucleotide polymorphism (SNP) in the UGT1A3 gene (uridine diphosphate glucuronosyltransferase gene 1A3) and / or increased UGT1A3 gene expression is determined in a biological sample of the patient. Furthermore, the invention relates to oligonucleotides that can be used in the method, as well as diagnostic kits that use these oligonucleotides.